

Sun Pharma Advanced Research Company Limited

Regd Office: Sun Pharma Advanced Research Centre,
Akota Road, Akota, Vadodara – 390 020. Tel. : +91-265-2330815
CIN : L73100GJ2006PLC047837 Website : www.sparc.life

Statement of Unaudited Financial Results for the Quarter Ended June 30, 2018

` in Lakhs

Particulars	Quarter ended			Year ended
	30.06.2018	31.03.2018	30.06.2017	31.03.2018
	Unaudited	Audited	Unaudited	Audited
		(Refer Note 5)		
Revenue from Operations	1,681	2,009	2,339	7,826
Other Income	123	52	126	494
Total Income	1,804	2,061	2,465	8,320
Expenses				
Cost of Materials Consumed	288	515	1,542	2,681
Employee Benefits Expenses	2,043	2,430	2,523	10,093
Clinical Trial Expenses	3,066	1,136	4,162	11,736
Professional charges	1,671	1,712	1,132	4,619
Finance Costs	2	1	7	12
Depreciation and Amortisation Expenses	190	202	206	818
Other Expenses	992	715	777	2,959
Total Expenses	8,252	6,711	10,349	32,918
Profit / (Loss) before exceptional items and tax	(6,448)	(4,650)	(7,884)	(24,598)
Exceptional item (Income) (Refer Note 3)	-	4,898	-	4,898
Profit / (Loss) before tax	(6,448)	248	(7,884)	(19,700)
Tax Expense	-	-	-	-
Profit / (Loss) for the period	(6,448)	248	(7,884)	(19,700)
Other Comprehensive Income (OCI) (net of tax)				
Items that will not be reclassified to profit and loss (Net actuarial loss on employee defined benefit obligation)	(40)	(104)	(13)	(143)
Total Comprehensive Income	(6,488)	144	(7,897)	(19,843)
Paid-up Equity Share Capital (Face Value ` 1 each)	2,509	2,509	2,469	2,509
Basic and Diluted Earnings Per Share of ` 1 each	(2.57)	0.10	(3.19)	(7.94)
	Not Annualised	Not Annualised	Not Annualised	

See accompanying notes to the financial results

Notes :

- 1 The above unaudited financial results are as per the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and have been taken on record by the Board of Directors at its meeting held on July 30, 2018 after being reviewed by the Audit Committee and have been subjected to a limited review by Statutory Auditors of the Company.
- 2 The Company has only one reportable business segment namely 'Pharmaceutical Research & Development'.
- 3 Exceptional item represents sale of premises of the Company at Tandajja, Vadodara.
- 4 Ind AS 115 - Revenue from contracts with customers is mandatory for accounting periods commencing on April 1, 2018. The Company has elected to apply the cumulative catch-up method on the date of transition, hence, the revised standard is applied to contracts that were in progress as of April 1, 2018. Accordingly, the comparatives have not been retrospectively adjusted. The adoption of the standard does not have any material impact on the financial results of the Company for the quarter ended June 30, 2018.
- 5 Figures for the quarter ended March 31, 2018 are balancing figures between the audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter of the same financial year.
- 6 Previous period figures have been regrouped / rearranged, wherever necessary, to correspond to current period's presentation.

By order of the Board

Dilip S. Shanghvi
Chairman and Managing Director

Vadodara, July 30, 2018